. Therefore, in order to prevent rabies, preventive
vaccination must be applied to dogs, cats and similar animals. However, the
homemade attenuated rabies living animal vaccines that are in current,
widespread use were long ago phased out in Europe and America. The World
Health Organisation has also clearly expressed that they do not support its
use because of its safety and questionable immunisation effects (especially
as the source of the toxin used for manufacturing the attenuated living
vaccine is showing signs of Atavism. The immunisation effect is also poor.)
Therefore, there are serious hidden safety problems in the use of this
vaccine.
Inactivated rabies vaccines represent the development trend of rabies
preventative measures for animals, which has been widely applied in
advanced countries. However due to its strict development conditions, there
are no homemade supplies available in the domestic market. The imported
inactivated vaccine is expensive, so it is difficult to be promoted
extensively in China. Facing such a large dog-breeding market and the
severe need for rabies prevention, it is imperative to produce homemade
inactivated rabies. Therefore, the inactivated rabies vaccine produced by
Changzhou Tongtai Bio- pharmaceutical Co., Ltd. will provide a safe, highly
effective and low-cost option.
Professor Fu Zhenfang contributed his technology to the project and
holds 65% of the shares. He is currently a professor working in the
graduate school's pathology and epidemiology departments in the veterinary
institute of Georgia University, US. As a famous virus specialist, he is an
authoritative figure in the field of bio-products for animal use,
especially in the research of rabies. His laboratory has mastered several
manufacturing technologies, including inactivated rabies vaccine,
parvovirus, hepatitis, canine distemper, and parainfluenza. They have
independent intellectual property rights for core technologies of
inactivated rabies vaccines
'/>"/>
SOURCE National High-Tech District, Changzhou Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 Related biology technology :1.
Avastin Used in Combination with Drugs from Bristol-Myers Squibb Has Advantages in Survival Rates Over the Current Sales-Leading Therapy for Advanced Ovarian Cancer2.
United BioSource Acquires Leading Publication Planning Software and Services Company3.
Leading Geneticist Francis Collins Named First Recipient of the Inamori Ethics Prize at Case Western Reserve University4.
CyberKnife Prostate Cancer Planning Study Published in Leading Radiation Oncology Journal5.
PAREXEL Appoints Leading Central Nervous System Experts to Its Global Clinical Pharmacology Business6.
Dragon retains leading investor relations firm7.
PAREXEL Appoints Leading Biopharmaceutical Marketing Expert Jacque Fisher to Medical Communications Services Executive Team8.
Halogen Customers Shape Industry-Leading Employee Performance and Talent Management Solution9.
PAREXEL to Present Leading Insights Regarding Key Industry Topics at 20th Annual Drug Information Association EuroMeeting10.
ZyGEM Appoints Leading Biotechnology Expert to Head Clinical Advisory Board11.
Cord Blood America CEO Matthew Schissler Interviewed by BIONOVA, Greeces Leading Biotech Magazine